Dostarlimab-Based Combinations in Advanced Endometrial Cancer – The ASCO Post
Statistically significant and clinically meaningful overall survival results from Part 1 and progression-free survival results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial in adult patients with primary advanced or recurrent endometrial cancer were presented in a late-breaking plenary session at the Society of Gynecologic Oncology’s (SGO) 2024 Annual Meeting on Women’s Cancer. The goal of the RUBY phase III trial program is to evaluate which patients with primary advanced or recurrent